Myeloma cell therapies, now in pharma hands, move into spotlight

Myeloma cell therapies, now in pharma hands, move into spotlight

10 Takeover Targets to Watch This Fall

10 Takeover Targets to Watch This Fall

5 questions ESMO cancer drug data might answer

5 questions ESMO cancer drug data might answer

Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival